Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026
Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026
Company Deals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Fineline Cube Mar 26, 2026
Company Deals

Insilico Medicine Expands AI Collaboration with Tenacia Bio – $94.75M Deal Targets CNS Drug Discovery with Blood-Brain Barrier Penetration

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Fineline Cube Mar 26, 2026
Company Drug

United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los

Fineline Cube Mar 26, 2026
Company Drug

WinHealth’s Ravicti Receives Orphan Drug Designation in Taiwan

Fineline Cube Oct 28, 2022

China-based Hong Kong WinHealth Pharma Group Ltd announced that its Swiss partner Immedica Pharma AB’s...

Company Drug

Lee’s Pharmaceutical’s NVK-002 Shows Strong Results in Phase III CHAMP Study

Fineline Cube Oct 28, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced that...

Company Drug

CSPC’s Antibody-Drug Conjugate SYS6002 Gains CDE Approval for Clinical Study

Fineline Cube Oct 28, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company

Luye Pharma’s Long-Acting IL-4Rα Antibody BA2101 Gains CDE Approval

Fineline Cube Oct 28, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its controlling subsidiary Shandong Boan Biotechnology Co.,...

Company Drug

Ausper Biopharma’s COVID-19 Nasal Spray Antibody Gets NMPA Approval

Fineline Cube Oct 28, 2022

Ausper Biopharma Inc., a Hangzhou-based developer of hepatitis B virus (HBV) drugs, announced that its...

Company

Merck’s Q3 Sales Rise on Key Drug Performances, China Growth

Fineline Cube Oct 28, 2022

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) reported its Q3 2022 financial results,...

Company Deals

Salubris Partners with Anlong Bio for Small Nucleic Acid Drugs in Hypertension

Fineline Cube Oct 28, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with Beijing...

Policy / Regulatory

Shanghai Launches Inhaled COVID-19 Vaccine Booster Program

Fineline Cube Oct 28, 2022

On October 25, Shanghai began accepting patient reservations for the inhalable recombinant COVID-19 vaccine (adenovirus...

Company Drug

Ocumension Initiates Second Phase III Denali Study for OT-301 in US

Fineline Cube Oct 27, 2022

China-based Ocumension Therapeutics (HKG: 1477) announced the initiation of a second Phase III Denali study...

Company R&D

Nankai University Establishes Postgraduate Practice Base with China Resources Biopharma

Fineline Cube Oct 27, 2022

The College of Pharmacy at Nankai University has established a postgraduate practice base at the...

Company Deals

Yiming and WZ Biosciences Collaborate on mRNA Process Platform

Fineline Cube Oct 27, 2022

China-based Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, and compatriot firm WZ...

Company Drug

BeiGene’s Brukinsa Receives Multiple Marketing Approvals in Latin America

Fineline Cube Oct 27, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced receiving multiple marketing approvals...

Company Drug

Zhaoke Ophthalmology Completes Enrollment for Intrarosa Phase III Trial

Fineline Cube Oct 27, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has completed...

Company Deals

JW Therapeutics Partners with 2seventy bio to Develop Cell Therapy Platform

Fineline Cube Oct 27, 2022

China-based JW Therapeutics (HKG: 2126) has entered into a partnership with US firm 2seventy bio...

Company Drug

Ascletis Pharma Files IND for Monkeypox Antiviral ASC10 with FDA

Fineline Cube Oct 27, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced the submission of an Investigational New Drug (IND)...

Company Drug

Simcere Receives FDA Clearance for Clinical Study of SIM0237

Fineline Cube Oct 27, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the US...

Company

Ping An Life Insurance Reports Q3 Results, Advances Healthcare Strategy

Fineline Cube Oct 27, 2022

Ping An Life Insurance Company of China Ltd released its 2022 Q3 financial report, showing...

Company Drug

United Labs Gains NMPA Approval for Ozempic Biosimilar IND

Fineline Cube Oct 27, 2022

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products...

Policy / Regulatory

China’s NMPA Issues New Drug Recall Management Measures

Fineline Cube Oct 27, 2022

The National Medical Products Administration (NMPA) has released the “Drug Recall Management Measures,” which took...

Company Medical Device

AccuMedical’s Blood Flow-Guided Stent Wins NMPA Approval for Brain Aneurysms

Fineline Cube Oct 27, 2022

AccuMedical Beijing Ltd has secured approval from China’s National Medical Products Administration (NMPA) for its...

Posts pagination

1 … 585 586 587 … 641

Recent updates

  • China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years
  • Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%
  • GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market
  • Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy
  • Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Company

Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%

Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Company Drug

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.